According to CRI’s market research, the sales of Propofol in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the new crown epidemic on the overall medical diagnosis and treatment services, the sales decreased from CNY1.232 billion in 2019 to CNY1.308 billion in 2020, with a year-on-year decrease of 14.28%. The CAGR of sales of Propofol in China from 2016 to 2020 is 1.89%.

CRI expects that the sales of Propofol will have a restorative growth from 2021 to 2025 with the effective alleviation of the new crown epidemic. In addition, Propofol has a fast onset, stable induction, and rapid and complete recovery. Based on these advantages, the sales volume of Propofol will increase steadily in the future. Moreover, Propofol is also used in veterinary clinical anesthesia. With the expansion of China’s pet market and servitization and standardization of pet hygiene, Propofol will also expand in the pet medicine market, driving the growth of its sales and sales volume

Topics Covered:
-The impact of COVID-19 on China’s Propofol market
– Sales value of China’s Propofol 2016-2020
– Competitive landscape of China’s Propofol market
– Prices of Propofol in China
– Prices of Propofol in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Propofol market
– Prospect of China’s Propofol market from 2021 to 2025

The post Investigation Report on China’s Propofol Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales of PEG-rhG-CSF in the Chinese market have increased year by year from 2016 to 2020. Among them, the sales growth in 2017 was the most obvious, from CNY126 million in 2016 to CNY449 million in 2017, with an annual growth rate of 256.08%. The main reason for the sharp increase is that PEG-rhG-CSF was included in China Medical Insurance in 2017 and the approval of indication was leukemia. The price reduction led to a large increase in sales. The CAGR of sales of PEG-rhG-CSF is about 97.58% from 2016 to 2020.

CRI analyzes that the sales volume of PEG-rhG-CSF will keep a growth trend from 2021 to 2025 due to the rapid increase in the number of patients. In China, about 40,000 leukemia patients are newly diagnosed every year. This situation led to a growth in the sales volume of PEG-rhG-CSF, which has the advantages of convenience, stability, high efficiency, and approval of indications. In addition, due to the use of PEG-rhG-CSF for non-medullary malignant tumors, the number of indications approved for China’s medical insurance is likely to rise, and the sales and the sales volume will also have the potential to grow.

Topics Covered:
-The impact of COVID-19 on China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
– Sales value of China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2016-2020
– Competitive landscape of China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
– Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China
– Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
– Prospect of China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market from 2021 to 2025

The post Investigation Report on China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales of Dasatinib have increased year by year from 2016 to 2020, with the most significant growth in 2018. The annual growth rate is 48.72 % from CNY51 million in 2017 to CNY75 million in 2018. The main reason for the increase is that China has undertaken an effort to cut healthcare costs, requiring insurance to cover 70% of costs since the national drug price negotiations in 2017. The CAGR of Dasatinib sales in 2016-2020 is 28.55%.

CRI analyzes that its sales will have an upward trend from 2021 to 2025 as the Chinese Dasatinib market expands. At present, 3 companies in China are in the approval stage of Dasatinib generic drugs. After the success of the approvals, the competition in the Chinese Dasatinib market will become more intense and the price will be less than before. Hence, the sales volume will increase accordingly. In addition, Dasatinib has been approved for 4 indications internationally, and only 2 indications have been approved in China. The number of indications approved in China is likely to increase, then sales still have the potential to increase.

Topics Covered:
-The impact of COVID-19 on China’s Dasatinib market
– Sales value of China’s Dasatinib 2016-2020
– Competitive landscape of China’s Dasatinib market
– Prices of Dasatinib in China
– Prices of Dasatinib in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Dasatinib market
– Prospect of China’s Dasatinib market from 2021 to 2025

The post Investigation Report on China’s Dasatinib Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, from 2016 to 2019, Abiraterone’s sales in the Chinese market have shown an upward trend. In 2017, the price of Abiraterone dropped and it was included in China’s national medical insurance. Therefore, the sales of Abiraterone in the Chinese market increased the most significantly from 2017 to 2019. The annual sales revenue in 2019 is CNY566.84 million, which increased over 30 times compared to that in 2016. The outbreak of the COVID-19 epidemic in 2020 has impacted the overall diagnosis and treatment business of Chinese hospitals, so the sales value of Abiraterone in the Chinese market declined slightly in 2020. The CAGR of Abiraterone sales value in the Chinese market from 2016 to 2020 is 140.7%.

CRI analyzes that from 2021 to 2025, Abiraterone’s sales in China will continue to grow as the improvement of COVID-19 epidemic. According to data from China National Cancer Registration Institute, prostate cancer has become the most common tumor in male urinary malignancies since 2008. As the incidence and mortality of this cancer continue to rise, and its sales will also increase.

Topics Covered:
-The impact of COVID-19 on China’s Abiraterone market
– Sales value of China’s Abiraterone 2016-2020
– Competitive landscape of China’s Abiraterone market
– Prices of Abiraterone in China
– Prices of Abiraterone in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Abiraterone market
– Prospect of China’s Abiraterone market from 2021 to 2025

The post Investigation Report on China’s Abiraterone Market 2021-2025 first appeared on CRI Report.

Golimumab is an immunosuppressive medication that can effectively regulate inflammation and bone metabolism. The trade name of Golimumab is SIMPONI, which was developed by Janssen Biologics BV. Its products were launched in China for the treatment of ankylosing spondylitis（AS）and rheumatoid arthritis (RA) in 2018. As of the first half of 2021, Janssen Biologics BV is the only manufacturer in the Chinese Golimumab market.

According to CRI’s market research, the sales of Golimumab in the Chinese market have had a rapid upward trend from 2018 to 2020. The annual sales revenue in 2020 is CNY6.32 million, which increased over 10 times compared to that in 2018. The CAGR of Golimumab sales in the Chinese market in 2018-2020 is 242.6%. The main reason for the rapid growth is that Golimumab was included in China’s medical insurance in 2019 and it entered the national medical insurance category B list in the field of rheumatism.

CRI analyzes that from 2021 to 2025，the sales will continue to increase due to its superior efficacy and low injection frequency. In addition, Golimumab will have a very broad market and the penetration rate of SIMPONI can be improved in the future. Therefore, the market share of Golimumab has the potential to increase, which will lead the sales volume to grow in the future.

Topics Covered:
-The impact of COVID-19 on China’s Golimumab market
– Sales value of China’s Golimumab 2016-2020
– Competitive landscape of China’s Golimumab market
– Prices of Golimumab in China
– Prices of Golimumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Golimumab market
– Prospect of China’s Golimumab market from 2021 to 2025

The post Investigation Report on China’s Golimumab Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales of Piperacillin and Tazobactam in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the new crown epidemic on the overall medical diagnosis and treatment services, the sales decreased from CNY1.681 billion in 2019 to CNY1.436 billion in 2020, with a year-on-year decrease of 14.6%. The CAGR of sales of piperacillin sodium and tazobactam sodium from 2016 to 2020 is 3.28%.

CRI predicts that the sales of Piperacillin and Tazobactam will have a restorative growth from 2021 to 2025 with the effective alleviation of the Covid-19 epidemic. In addition, Piperacillin/Tazobactam has good clinical effects and few adverse reactions. Piperacillin/Tazobactam is more effective and safer for the treatment of lower respiratory tract infections and urinary tract infections caused by beta-lactamase-producing strains compared with similar drugs. Based on these advantages, the sales of piperacillin and tazobactam will increase steadily in the future.

Topics Covered:
-The impact of COVID-19 on China’s Piperacillin and Tazobactam market
– Sales value of China’s Piperacillin and Tazobactam 2016-2020
– Competitive landscape of China’s Piperacillin and Tazobactam market
– Prices of Piperacillin and Tazobactam in China
– Prices of Piperacillin and Tazobactam in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Piperacillin and Tazobactam market
– Prospect of China’s Piperacillin and Tazobactam market from 2021 to 2025

The post Investigation Report on China’s Piperacillin and Tazobactam Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales of Tiotropium Bromide in the Chinese market have been on the rise from 2016 to 2019. Especially after the inhalation powder of Tiotropium Bromide was included in the national medical insurance catalog in 2017, its sales have grown steadily from 2017 to 2019. However, its sales fell 19.3% year-on-year to CNY274 million in 2020. The main reason for the decline in its sales is that the COVID-19 epidemic has impacted the hospital’s overall diagnosis and treatment business. The CAGR of Tiotropium Bromide in the Chinese market from 2016 to 2020 is 4.73%.

CRI predicts that with the effective alleviation of the COVID-19 epidemic, the sales volume of Tiotropium Bromide in the Chinese market from 2021 to 2025 will have a restorative growth, promoting the increase in sales. As of the end of 2020, the number of chronic resistance disease patients in China has increased to more than 100 million. Therefore, the sales of Tiotropium Bromide will continue to grow, promoting the growth of the Tiotropium Bromide market.

Topics Covered:
-The impact of COVID-19 on China’s Tiotropium Bromide market
– Sales value of China’s Tiotropium Bromide 2016-2020
– Competitive landscape of China’s Tiotropium Bromide market
– Prices of Tiotropium Bromide in China
– Prices of Tiotropium Bromide in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Tiotropium Bromide market
– Prospect of China’s Tiotropium Bromide market from 2021 to 2025

The post Investigation Report on China’s Tiotropium Bromide Market 2021-2025 first appeared on CRI Report.

According to CRI analysis, the sales of Compound Amino Acids in the Chinese market have basically maintained a slow growth from 2016 to 2020, reaching about 1.53 billion in 2020, and the CAGR from 2016 to 2020 is about 1.8%. The main reason is that the clinical demand for Compound Amino acids is relatively stable.

CRI predicts that with the development of Compound Amino Acid categories from 2021 to 2025, the number of indications will increase so that sales and sales volume have potential for growth. Moreover, with the addition of new manufacturers in the Chinese Compound Amino Acid market, market competition will become increasingly fierce and sales will increase as prices fall.

Topics Covered:
-The impact of COVID-19 on China’s Compound Amino Acid market
– Sales value of China’s Compound Amino Acid 2016-2020
– Competitive landscape of China’s Compound Amino Acid market
– Prices of Compound Amino Acid in China
– Prices of Compound Amino Acid in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Compound Amino Acid market
– Prospect of China’s Compound Amino Acid market from 2021 to 2025

The post Investigation Report on Chinese Compound Amino Acid Market 2021-2025 first appeared on CRI Report.

According to CRI analysis, the sales of Esomeprazole have grown steadily from 2016 to 2019. In 2020, its sales fell by about 6% to CNY1.561 billion in 2020. The main reason is that the Covid-19 epidemic has affected the hospital’s overall diagnosis and treatment business, resulting in a decline in its sales. The CAGR of Esomeprazole sales in the Chinese market from 2016 to 2020 is 12%.

CRI predicts that the sales volume of Esomeprazole in the Chinese market will have a restorative growth from 2021 to 2025 with the effective alleviation of the Covid-19 epidemic. In addition, as of the first half of 2021, there are 13 pharmaceutical companies that have applied to enter the Esomeprazole market in China. It can be expected that the price of Esomeprazole will decrease with the addition of new manufacturers, and both sales and sales volume will grow. Moreover, compared with similar drugs, Esomeprazole has the advantages of short-course therapy, stable curative effect, fast and long-lasting effect, so the sales volume of Esomeprazole in China will maintain a growth trend.

Topics Covered:
-The impact of COVID-19 on China’s Esomeprazole market
– Sales value of China’s Esomeprazole 2016-2020
– Competitive landscape of China’s Esomeprazole market
– Prices of Esomeprazole in China
– Prices of Esomeprazole in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Esomeprazole market
– Prospect of China’s Esomeprazole market from 2021 to 2025

The post Investigation Report on China’s Esomeprazole Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales of Dolutegravir in the Chinese market have had an upward trend from 2016 to 2020. Due to the advantages of Dolutegravir, such as good tolerability, drug resistance, and convenience of taking drugs, its sales in the Chinese market have grown rapidly, from CNY0.2 million in 2016 to CNY3.14 million in 2017, with an annual growth rate of 1392.89%. In 2020, sales of Dolutegravir fell by 12.92%. The main reason for a decline in its sales is that the COVID-19 epidemic has impacted the hospital’s overall diagnosis and treatment business. Dolutegravir has a CAGR of 166.14% from 2016 to 2020.

CRI predicts the sales of Dolutegravir will increase from 2021 to 2025 with the increase in the number of AIDS patients. The number of surviving HIV-infected people in China increased from 958,000 in 2019 to 1.045 million in 2020, with a growth rate of 9%. The number of new infections shows an increasing trend. Therefore, sales of Dolutegravir used to treat HIV infection will continue to increase. In addition, with the effective alleviation of the COVID-19 epidemic, the sales of Dolutegravir will have a restorative growth from 2021 to 2025.

Topics Covered:
-The impact of COVID-19 on China’s Dolutegravir market
– Sales value of China’s Dolutegravir 2016-2020
– Competitive landscape of China’s Dolutegravir market
– Prices of Dolutegravir in China
– Prices of Dolutegravir in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Dolutegravir market
– Prospect of China’s Dolutegravir market from 2021 to 2025

The post Investigation Report on China’s Dolutegravir Market 2021-2025 first appeared on CRI Report.